Portmann et al. have demonstrated that inhibiting SIRT1 leads to impaired tumour growth both in vivo and in vitro and this supports the notion that SIRT1 activity in healthy hepatocytes protects against cancer, but after transformation, SIRT1 becomes a protective force for the tumour cells as a survival advantage [193]. This evidence concerns the gene SIRT1 and neoplasm.